Genomtec S.A. (WSE:GMT)

Market Cap	72.76M -31.6%
Revenue (ttm)	30.00K +400.0%
Net Income	-9.21M
EPS	-0.61
Shares Out	15.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,472
Open	4.910
Previous Close	4.980
Day's Range	4.830 - 5.140
52-Week Range	3.245 - 7.330
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 1, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 32
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GMT

Financial Performance

In 2025, Genomtec's revenue was 19,000, an increase of 1800.00% compared to the previous year's 1,000. Losses were -10.22 million, -8.80% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error